Overview

Symptomatic Therapy for Patients With Huntington's Disease

Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Based on the previous symptomatic treatment of Chinese HD patients, this study intends to further optimize the treatment regimen of Chinese HD patients so as to further improve the prognosis of patients.
Phase:
Phase 1
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Treatments:
Haloperidol
Haloperidol decanoate
Idebenone
Risperidone
Sertraline
Tetrabenazine
Ubiquinone